Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00049101 · ClinicalTrials.gov registry record · Phase 1
Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00049101: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00049101 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00049101, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Combining erlotinib with combination chemotherapy may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combining erlotinib with oxaliplatin, leucovorin, and fluorouracil in treating patients who have metastatic colorectal cancer.
Interventions
- DRUG oxaliplatin
- DRUG fluorouracil
- DRUG leucovorin calcium
- DRUG erlotinib hydrochloride
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-08 |
| Est. Completion | 2004-08 |
| Phase | Phase 1 |
What the finished NCT00049101 record still lists
NCT00049101 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 4 interventions - of which oxaliplatin is the first listed.
NCT00049101 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00049101 about?
NCT00049101 is a clinical study titled "Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Combining erlotinib with combination chemotherapy may kill more tumor cells. ...
What is the current status of trial NCT00049101?
This trial is currently completed. It is a Phase 1 study. The study started on 2002-08. Estimated completion is 2004-08.
What interventions are being tested in trial NCT00049101?
The interventions under investigation include: oxaliplatin (DRUG), fluorouracil (DRUG), leucovorin calcium (DRUG), erlotinib hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00049101?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia